CollaRx®
Products developed using the CollaRx® technology may be designed either as a lyophilized porous sponge or as a transparent/translucent sheet (or "membrane") about 20 to 80 μm in thickness.
Both sponge and membrane formats can be implanted at the time of surgery or applied topically to chronic or acute/traumatic wounds. The CollaRx matrices are biodegraded and fully resorbed within one to seven weeks according to implant location (i.e. well vascularized areas versus bone cavities). The in vivo release of drug from the CollaRx matrix takes place via a combination of diffusion and natural breakdown of the collagen to provide both rapid and prolonged release, which can be controlled through formulation techniques and processing variables.
The CollaRx sponge forms the basis of Innocoll's lead commercial product, Gentamicin Surgical Implant, currently marketed in Europe and in advanced stage of clinical development for the US. The CollaRx membrane is the basis of Innocoll's CollaGUARD™ advanced wound care product, which is approved in Europe (as a class III medical device) and the US (marketed as Collieva™).